

IDS - 03/24/2004

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Complete if Known

Application Number	09/893,344
Filing Date	6/28/2001
First Named Inventor	M. EISENBACK-SCHWARTZ
Group Art Unit	1646
Examiner Name	J. Andres

Attorney Docket Number

EIS-SCHWARTZ=21

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Office <sup>3</sup>	Foreign Patent Number	Kind Code <sup>4</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
DK	AA	WO	99/34827	A1	Yeda Res & Devel Co. Ltd	07-15-1999		

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published						
DK	AB	CADY et al, "Response of Murine $\gamma\delta$ T Cells to the Synthetic Polypeptide Poly-Glu <sup>50</sup> Tyr <sup>50</sup> , <i>J Immunol</i> 165(4):1790-1798 (2000)						
DK	AC	DRACH et al, "Suppressive effect of synthetic polypeptide GT on the induction of delayed-type hypersensitivity to a complex GT + methylated bovine serum albumin", <i>Annales D'Immunologie, France</i> 131D(3):299-307 (1980)						
DK	AD	HAVENITH et al, "T Cell Priming <i>In Situ</i> by Intratracheally Instilled Antigen-pulsed Dendritic Cells", <i>Am J Respir Cell Mol Biol</i> 9(5):484-488 (1993)						
DK	AE	LEI et al, "Regulation of Immune Responses by I-J Gene Products; III. GT-specific Suppressor Factor is Composed of Separate I-J and Idiotype-bearing Chains", <i>J Immunol</i> 130(3):1274-1279 (1983)						
DK	AF	VIDOVIC et al, "Recessive T Cell Response to Poly (Glu <sup>50</sup> Tyr <sup>50</sup> ) Possibly Caused by Self Tolerance", <i>J Immunol</i> 134(6):3563-3568 (1985)						
DK	AG	Hauben et al, (1 September 2000) "Passive or Active Immunization with Myelin Basic Protein Promotes Recovery from Spinal Cord Contusion," <i>The Journal of Neuroscience</i> 20(17): 6421-6430						
DK	AH	Hauben et al, (August 2001) "Posttraumatic Therapeutic Vaccination with Modified Myelin Self-Antigen Prevents Complete Paralysis While Avoiding Autoimmune Disease," <i>The Journal of Clinical Investigation</i> 108(4): 591-599						
DK	AI	FISHER et al, (1 January 2001) "Vaccination for Neuroprotection in the Mouse Optic Nerve: Implications for Optic Neuropathies," <i>The Journal of Neuroscience</i> 21(1): 136-142						
DK	AJ	SCHORI et al, (13 March 2001) "Vaccination for Protection of Retinal Ganglion Cells Against Death from Glutamate Cytotoxicity and Ocular Hypertension: Implications for Glaucoma," <i>PNAS</i> 98(6): 3398-3403						

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

DK	AK	SUCHER et al, (1997) "Molecular Basis of Glutamate Toxicity in Retinal Ganglion Cells," Vision Res. 37(24): 3483-3493	
DK	AL	SCHORI et al,(2001) "T-Cell Based Immunity Counteracts the Potential Toxicity of Glutamate in the Central Nervous System," Journal of Neuroimmunology. 119(2): 199-204	
DK	AM	Stedman's Medical Dictionary (2002), Physicians' Desk Reference, Medical Economics Company Inc.	

Examiner Signature	/Daniel Kolker/ (05/24/2006)	Date Considered	05/24/2006
--------------------	------------------------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Approved for use through 07/31/2008. GMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

of

**Complete if Known**

Application Number 10/807,414

**Filing Date** March 24, 2004

First Named Inventor Michal Eisenbach-Schwartz

Group Art Unit

**Examiner Name**

Number EIS-SCHWARTZ21A

Sheet 1 of 2 Attorney Docket Number EIS-SCHWARTZ21A

## U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Signature	/Daniel Kolker/ (05/24/2006)	Date Considered	05/24/2006
-----------------------	------------------------------	--------------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.4. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

## Complete If Known

Application Number	10/807,414
Filing Date	March 24, 2004
First Named Inventor	Michal Eisenbach-Schwartz
Group Art Unit	1647
Examiner Name	

Attorney Docket Number

EIS-SCHWARTZ21A

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
DK	AP	ANGELOV et al, "Therapeutic vaccine for acute and chronic motor neuron diseases: implications for amyotrophic lateral sclerosis", <u>Proc Natl Acad Sci USA</u> 100(8):4790-4795 (2003)	
DK	AQ	DEBRÉ et al, "Genetic control of specific immune suppression. II. H-2-linked dominant genetic control of immune suppression by the random copolymer L-glutamic acid <sup>50</sup> -L-tyrosine <sup>50</sup> (GT)", <u>J Exp Med</u> 142(6):1447-1454 (1975)	
DK	AR	HIRSCHBERG et al, "Accumulation of passively transferred primed T cells independently of their antigen specificity following central nervous system trauma", <u>J Neuroimmunol</u> 89(1-2):88-96 (1998)	
DK	AS	KIPNIS et al, "T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: possible therapy for optic neuropathies.", <u>Proc Natl Acad Sci USA</u> 97(13):7446-7451 (2000)	
DK	AT	KIPNIS et al, "Myelin specific Th1 cells are necessary for post-traumatic protective autoimmunity", <u>J Neuroimmunol</u> 130(1-2):78-85 (2002)	
DK	AU	KIPNIS et al, "Neuroprotective autoimmunity: naturally occurring CD4 <sup>+</sup> CD25 <sup>+</sup> regulatory T cells suppress the ability to withstand injury to the central nervous system", <u>Proc Natl Acad Sci USA</u> 99(24):15620-15625 (2002)	
DK	AV	MOALEM et al, "Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy", <u>Nat Med</u> 5(1):49-55 (1999)	
DK	AW	SCHWARTZ et al, "Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries", <u>Trends Mol Med</u> 7(6):252-258 (2001)	
DK	AX	SEO et al, "Activation of murine epidermal V $\gamma$ 5/V $\delta$ 1-TCR $^+$ T cell lines by Glu-Tyr polypeptides", <u>J Invest Dermatol</u> 116(6):880-885 (2001)	
DK	AY	YOLES et al, "Protective autoimmunity is a physiological response to CNS trauma", <u>J Neurosci</u> 21(11):3740-3748 (2001)	

Examiner  
Signature

/Daniel Kolker/ (05/24/2006)

Date  
Considered

05/24/2006

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.